Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

forbes.com - Anna Forsythe - Why Pharma Needs To Rethink The Systematic Literature Review
Why Pharma Needs To Rethink The Systematic Literature Review
Forbes

​Anna Forsythe, pharmacist & health economist, is Founder & President of Oncoscope-AI, a real-time oncology evidence platform. I have worked with pharmaceutical evidence for more than 25 years, and I don't think I have ever seen it move as…

marketbeat.com - Jefferies Financial Group Inc. Buys New Position in Urogen Pharma $URGN
Jefferies Financial Group Inc. Buys New Position in Urogen Pharma $URGN
MarketBeat

Jefferies Financial Group Inc. acquired a new position in Urogen Pharma (NASDAQ:URGN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired…

marketbeat.com - Coastal Bridge Advisors LLC Invests $1.36 Million in Urogen Pharma $URGN
Coastal Bridge Advisors LLC Invests $1.36 Million in Urogen Pharma $URGN
MarketBeat

Coastal Bridge Advisors LLC bought a new stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 37,000 shares of the…

marketbeat.com - Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by HC Wainwright to Strong-Buy Rating
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by HC Wainwright to Strong-Buy Rating
MarketBeat

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was upgraded by investment analysts at HC Wainwright to a 'strong-buy' rating in a research note issued to investors on Thursday, Zacks.com reports. Can BioMarin Stock Live Up to Wall Street's…

marketbeat.com - Palo Alto Investors LP Purchases New Shares in Urogen Pharma $URGN
Palo Alto Investors LP Purchases New Shares in Urogen Pharma $URGN
MarketBeat

Palo Alto Investors LP bought a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 24,500 shares of the company's…

marketbeat.com - Stonepine Capital Management LLC Makes New Investment in Nuvectis Pharma, Inc. $NVCT
Stonepine Capital Management LLC Makes New Investment in Nuvectis Pharma, Inc. $NVCT
MarketBeat

Stonepine Capital Management LLC bought a new stake in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 40,000 shares of the…

marketbeat.com - Harvey Capital Management Inc. Takes $10.34 Million Position in BridgeBio Pharma, Inc. $BBIO
Harvey Capital Management Inc. Takes $10.34 Million Position in BridgeBio Pharma, Inc. $BBIO
MarketBeat

Harvey Capital Management Inc. purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional…

marketbeat.com - Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Still a Buy?
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Still a Buy?
MarketBeat

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) gapped up before the market opened on Thursday. The stock had previously closed at $16.90, but opened at $18.42. Ascentage Pharma Group International shares last…

koreatimes.co.kr - Jhoo Dong-chan - KAIST unveils homegrown AI model for predicting protein structures, drug binding
KAIST unveils homegrown AI model for predicting protein structures, drug binding
The Korea Times

Researchers at the Korea Advanced Institute of Science and Technology (KAIST) said Friday they have developed a biomolecular artificial intelligence (AI) model, called K-Fold, that predicts protein structures and how drug candidates bind to them…

cnbc.com - Brad Quick - BioCryst is profitable. Now it wants to buy more rare disease drugs
BioCryst is profitable. Now it wants to buy more rare disease drugs
CNBC

BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to…

wsj.com - The Editorial Board - Opinion | You're Living Longer, Americans
Opinion | You're Living Longer, Americans
Wall Street Journal

Pessimists on the political left and right can't find much good to say about America these days, so allow us to help. American life expectancy hit a record in 2024 as deaths fell from most major causes, according to a Centers for Disease Control…

rediff.com - Surajeet Das Gupta - AI Effect: 'Nearly 3 Million Jobs Are At Risk In India
AI Effect: 'Nearly 3 Million Jobs Are At Risk In India
Rediff.com

In the next 36 months nearly 25 to 40 per cent of jobs will be under threat from AI and job losses are inevitable. It promises to get worse before getting better. On the one hand there is the fear that the speed of Artificial Intelligence adoption…

seekingalpha.com - High Alpha Professor - Diodes: Its Three-Year Targets Are Already Showing Up In Q3 Guidance (NASDAQ:DIOD)
Diodes: Its Three-Year Targets Are Already Showing Up In Q3 Guidance (NASDAQ:DIOD)
Seeking Alpha

Diodes Incorporated is achieving its three-year financial targets far ahead of schedule, driven by AI-related demand and improved factory utilization. Q3 guidance projects $510M revenue, 35% gross margin, and $1.05 EPS, with AI server and…

yahoo.com - Maham Fatima - A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path
A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path
Yahoo!

On August 13, Capricor Therapeutics (NASDAQ: CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company's bid to treat cardiomyopathy in Duchenne muscular dystrophy patients on…

irishtimes.com - Jack Horgan-Jones - Peter Burke asked colleague to 'intercede' with regulator over wastewater charge changes
Peter Burke asked colleague to 'intercede' with regulator over wastewater charge changes
The Irish Times

A Cabinet member has been asked to “intercede” with an independent regulator by Minister for Enterprise Peter Burke amid industry backlash over changes to the charging regime for commercial wastewater. The new regime –…

Receive a Daily briefing on Pharma Industry News

Get Started